March 15, 2018 / 10:13 AM / 2 years ago

BRIEF-Biocryst Announces Initiation Of The Phase 3 Apex-2 Trial Of BCX7353 In Patients With Hereditary Angioedema

March 15 (Reuters) - Biocryst Pharmaceuticals Inc:

* BIOCRYST ANNOUNCES INITIATION OF THE PHASE 3 APEX-2 TRIAL OF BCX7353 IN PATIENTS WITH HEREDITARY ANGIOEDEMA

* BIOCRYST PHARMACEUTICALS INC SEES REPORTING TOP-LINE RESULTS FROM APEX-2 PHASE 3 TRIAL IN FIRST HALF OF 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below